China's Sinopharm debuts new vaccines targeting COVID-19 variants
China's National Pharmaceutical Group Corporation (Sinopharm) unveiled a series of newly-developed COVID-19 vaccines and medicines at the 2021 China International Fair for Trade in Services (CIFTIS) on Saturday. Sinopharm have developed vaccines against coronavirus' Delta and Beta variants, said Zhu Jingjin, a project chief of Sinopharm, said at the fair. And its second-generation broad-spectrum recombinant protein vaccine is in trials, he added. The group said that it will expand its annual productivity to more than five billion doses in a bid to make China's COVID-19 vaccines global public goods.